Treatment of chronic heart failure in advanced chronic kidney disease: the HAKA multicenter retrospective real-world study
Cardiorenal Medicine · 2024
DOI: 10.1159/000538030 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cardiorenal Medicine, 2024. Verfasst von Borja Quiroga und 32 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, IIS-La Princesa, Hospital Universitario de la Princesa, Madrid, Spain. Hauptthemen laut MEDLINE: Heart Failure, Renal Insufficiency, Chronic, Mineralocorticoid Receptor Antagonists, Angiotensin Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Introduction
Chronic heart failure (HF) has high rates of mortality and hospitalization in patients with advanced chronic kidney disease (aCKD). However, randomized clinical trials have systematically excluded aCKD population. We have investigated current HF therapy in patients receiving clinical care in specialized aCKD units.
Methods
The Heart And Kidney Audit (HAKA) was a cross-sectional and retrospective real-world study including outpatients with aCKD and HF from 29 Spanish centers. The objective was to evaluate how the treatment of HF in patients with aCKD complied with the recommendations of the European Society of Cardiology Guidelines for the diagnosis and treatment of HF, especially regarding the foundational drugs: renin-angiotensin system inhibitors (RASi), angiotensin receptor blocker/neprilysin inhibitors (ARNI), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter-2 inhibitors (SGLT2i).
Results
Among 5012 aCKD patients, 532 (13%) had a diagnosis of HF. Of them, 20% had reduced ejection fraction (HFrEF), 13% mildly reduced EF (HFmrEF), and 67% preserved EF (HFpEF). Only 9.3% of patients with HFrEF were receiving quadruple therapy with RASi/ARNI, BB, MRA and SGLT2i, but the majority were not on the maximum recommended doses. None of the patients with HFrEF and CKD G5 received quadruple therapy. Among HFmrEF patients, approximately half and two-thirds were receiving RASi and/or BB, respectively, while less than 15% received ARNI, MRA or SGLT2i. Less than 10% of patients with HFpEF were receiving SGLT2i.
Conclusions
Under real-world conditions, HF in aCKD patients is sub-optimally treated. Increased awareness of current guidelines and pragmatic trials specifically enrolling these patients represent unmet medical needs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology Department, IIS-La Princesa, Hospital Universitario de la Princesa, Madrid, Spain.
- RICORS2040, Madrid, Spain.
- Nephrology Department, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain.
- Nephrology Department, Hospital Sant Joan Despí - Moisès Broggi, Consorci Sanitari Integral, Barcelona, Spain.
- Nephrology Department, Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain.
- Nephrology Department, Hospital San Pedro de Alcántara, Cáceres, Spain.
Zitieren
APA
Quiroga, B., Ortiz, A., Núñez, S., Kislikova, M., González Sanchidrián, S., Broseta, J. J., Albines, Z. S., Escamilla Cabrera, B., Rivero Viera, Y., Rodriguez Santarelli, D., Salanova Villanueva, L., Lopez Rodriguez, F., Cancho Castellano, B., Ibáñez Cerezon, M., Gutierrez Rivas, C. P., Aresté, N., Campos Gutiérrez, B., Ródenas Gálvez, A., Glucksmann Pizá, M. C., …, & Cardiorenal Medicine Group (CaReSEN) of the Spanish Society of Nephrology (2024). Treatment of chronic heart failure in advanced chronic kidney disease: the HAKA multicenter retrospective real-world study. Cardiorenal Medicine. https://doi.org/10.1159/000538030
Vancouver
Quiroga B, Ortiz A, Núñez S, Kislikova M, González Sanchidrián S, Broseta JJ, et al. Treatment of chronic heart failure in advanced chronic kidney disease: the HAKA multicenter retrospective real-world study. Cardiorenal Medicine. 2024. doi:10.1159/000538030
BibTeX
@article{Quiroga2024,
author = {Quiroga, Borja and Ortiz, Alberto and Núñez, Sara and Kislikova, Maria and González Sanchidrián, Silvia and Broseta, José Jesús and Albines, Zoila Stany and Escamilla Cabrera, Beatriz and Rivero Viera, Yaiza and Rodriguez Santarelli, David and Salanova Villanueva, Laura and Lopez Rodriguez, Francisca and Cancho Castellano, Barbara and Ibáñez Cerezon, María and Gutierrez Rivas, Carmen Patricia and Aresté, Nuria and Campos Gutiérrez, Belén and Ródenas Gálvez, Ana and Glucksmann Pizá, Maria Constanza and Balda Manzanos, Sagrario and Soldevila, Amparo and Rodríguez Gayo, Lucía and Moral Berrio, Esperanza and Ortega Diaz, Mayra and Beltrán Catalán, Sandra and Puente García, Adriana and Ángel Rojas, Miguel and Sosa Barrios, R Haridian and Santana Zapatero, Henar and Rangel Hidalgo, Gema and Martinez Canet, Ana Maria and Díez, Javier and Cardiorenal Medicine Group (CaReSEN) of the Spanish Society of Nephrology, Cardiorenal Medicine Group (CaReSEN) of the Spanish Society of Nephrology},
title = {Treatment of chronic heart failure in advanced chronic kidney disease: the HAKA multicenter retrospective real-world study},
journal = {Cardiorenal Medicine},
year = {2024},
doi = {10.1159/000538030}
}
EUVIMED